Skip to Content

BioNTech SE BNTX

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Raising Our BioNTech FVE to $139 on Strong COVID-19 Vaccine Revenue and Flu Prospects

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

We've raised our fair value estimate for BioNTech to $139 per share from $124 following first-quarter results, as we've raised our COVID-19 vaccine revenue projections slightly for the year and added potential revenue for an mRNA-based influenza vaccine beginning in 2024, but also raised our tax rate assumptions for the firm.

Read Full Analysis

Company Profile

Business Description

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.

Contact
An der Goldgrube 12
Mainz, D-55131, Germany
T +49 613190840
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 1,941

Related